In preclinical cancer models, it has been demonstrated that DLL4-Fc, a recombinant protein that mimics the binding of Delta-like ligand 4 (DLL4), activates Notch signaling and inhibits tumor development [101]. Here, DLL4 is linked to neoplasm.